nCounter® Metabolic Pathways Panel
Helping Your Research
Quantify the expression of hundreds of genes involved in core metabolic processes and immunometabolism for human or mouse samples in a reliable, simple, and robust way using the nCounter Metabolic Pathways Panel. Understand the complex mechanisms behind metabolic adaptation, metabolic switching, metabolic alterations, and study changes in mitochondrial respiration and glycolysis.
The Metabolic Pathways Panel helps advance efforts towards novel therapeutic targets that take advantage of altered metabolism in cancer and other diseases. Get results in less than 24 hours from multiple sample types with a workflow that maximizes insight and minimizes turnaround time:
- Quantify the presence and relative abundance of 14 different immune cell types for immunometabolism studies
- Bypass RT and amplification by direct detection, yielding highly reproducible data
- Process your samples with < 30 minutes hands-on time and get results in < 24 hours
How It Works
The underlying molecular mechanisms behind alterations in metabolic pathways, signaling pathways, and cell stress can now be fully elucidated, giving you a complementary tool to traditional metabolite assays for profiling metabolic checkpoints and potential therapeutic targets.
Directly profile 768 genes in human or mouse across 34 annotated pathways involved in five important themes for metabolism research:
Biosynthesis and Anabolic Pathways
Nutrient Capture and Catabolic Pathways
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
NanoString Technology for Human Papillomavirus Typing.
High-throughput HPV typing assays with increased automation, faster turnaround and type-specific digital readout would facilitate studies monitoring the impact of HPV vaccination. We evaluated the NanoString nCounter((R)) platform for detection and digital readout of 48 HPV types in a single reaction.
Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
PURPOSE: Patients with heterozygous gain-of-function (GOF) mutations in STAT1 frequently exhibit chronic mucocutaneous candidiasis (CMC), immunodeficiency and autoimmune manifestations. Several treatment options including targeted therapies and hematopoietic stem cell transplantation (HSCT) are available for STAT1 GOF patients but modalities and outcomes are not well established.
Tissue-specific endothelial cell heterogeneity contributes to unequal inflammatory responses.
Endothelial cells (EC) coordinate vascular homeostasis and inflammation. In organ transplantation, EC are a direct alloimmune target.